Report Overview

The Type Diabetes Mellitus drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Type Diabetes Mellitus also known as Non-Insulin Dependent Diabetes Mellitus refers to a defect in insulin secretion and sensitivity, whereby the -cells in the pancreas fail to secrete sufficient amounts of insulin and cells fail to uptake adequate amounts of insulin due to loss of sensitivity, commonly referred to as insulin resistance. The World Health Organization (WHO) estimates that the prevalence of Diabetes Mellitus in Kenya at 3.3% and predicts a rise to 4.5% by 2025. However, two-thirds of diabetics may be undiagnosed. Higher rates of diabetics are found in urban areas. Urbanisation and adoption of Western lifestyles have led many Kenyans towards risk for developing DM. Kenya has seen increase in the risk factors like abdominal obesity, poor dietary habits, excess alcohol consumption, smoking and physical inactivity.



Market Drivers

The market is majorly driven by the increasing prevalence of Type Diabetes Mellitus in Kenya. The Prevalence of type diabetes mellitus is 16% which is high for a rural community in Kenya where majority live on 1 dollar/day. About 1% of deaths in Kenya were directly attributable to Type Diabetes Mellitus in 2012.

Increasing initiatives by Government of Kenya by Implementation of National Diabetes Mellitus Strategy in 2015 has led to establishment of hospital Diabetes clinics in nine provinces of the country. A Diabetes Education Programme has also been implemented for healthcare staff.

Overall, Rise in the prevalence of TypeDiabetes Mellitus, Increased partnerships by private pharmaceutical companies like Sanofi and Novo Nordisk with the Ministry of Health, Kenya and increase in the healthcare expenditure are fuelling growth in Type Diabetes Mellitus treatment market in Kenya.

Diabetes Mellitus requires long-term follow up, with uninterrupted access to medication and specialist care. Low levels of public awareness, high cost of Insulin, non-adherence to treatment, poor behaviours towards Diabetes Mellitus and unwillingness to adopt healthier lifestyles are hindering growth of market.